Targeting synaptic dysfunction in Alzheimer's disease by administering a specific nutrient combination

Journal of Alzheimer's Disease

Volumn 38, Issue 3, 2014, Pages 459-479

  Van Wijk, Nick ^a   Broersen, Laus M ^a   De Wilde, Martijn C ^a   Hageman, Robert J J ^a   Groenendijk, Martine ^a   Sijben, John W C ^a   Kamphuis, Patrick J G H ^a,b  

^a DANONE NUTRICIA RESEARCH   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Alzheimer's disease; amyloid ; Fortasyn Connect; membrane; neurotransmission; nutrition; phospholipid; Souvenaid; synaptic dysfunction

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; CHOLINE; CYANOCOBALAMIN; DOCOSAHEXAENOIC ACID; FOLIC ACID; ICOSAPENTAENOIC ACID; PHOSPHOLIPID; PYRIDOXINE; SELENIUM; URIDINE;

ALZHEIMER DISEASE; BRAIN FUNCTION; CLINICAL EFFECTIVENESS; COGNITION; FORTASYN CONNECT; HUMAN; MEMBRANE FORMATION; MEMBRANE STRUCTURE; MEMORY DISORDER; NERVE CELL MEMBRANE; NEUROTRANSMISSION; NONHUMAN; NUTRIENT MANAGEMENT; NUTRIENT SOLUTION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SYNAPTIC MEMBRANE; SYNAPTIC POTENTIAL; SYNAPTIC TRANSMISSION;

ALZHEIMER'S DISEASE; AMYLOID-Β; FORTASYN CONNECT; MEMBRANE; NEUROTRANSMISSION; NUTRITION; PHOSPHOLIPID; SOUVENAID; SYNAPTIC DYSFUNCTION;

ALZHEIMER DISEASE; ANIMALS; BRAIN; DIETARY SUPPLEMENTS; HUMANS; NUTRITIONAL STATUS; SYNAPSES;

EID: 84889770932     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-130998     Document Type: Review

References (174)

1. Caselli RJ, Beach TG, Yaari R, Reiman EM (2006) Alzheimer's disease a century later. J Clin Psychiatry 67, 1784-1800.
2. Pereira C, Agostinho P, Moreira PI, Cardoso SM, Oliveira CR (2005) Alzheimer's disease-Associated neurotoxic mechanisms and neuroprotective strategies. Curr Drug Targets CNS Neurol Disord 4, 383-403.
3. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, JonesE(2011) Alzheimer's disease. Lancet 377, 1019-1031.
4. Selkoe DJ (2002) Alzheimer's disease is a synaptic failure. Science 298, 789-791.
5. Arendt T (2009) Synaptic degeneration in Alzheimer's disease. Acta Neuropathol 118, 167-179.
6. Davies CA, Mann DM, Sumpter PQ, Yates PO (1987) A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease. J Neurol Sci 78, 151-164.
7. Masliah E, Terry RD, Alford M, DeTeresa R, Hansen LA (1991) Cortical and subcortical patterns of synaptophysin like immunoreactivity in Alzheimer's disease. Am J Pathol 138, 235-246.
8. Koffie RM, HymanBT, Spires-JonesTL(2011) Alzheimer's disease: Synapses gone cold. Mol Neurodegener 6, 63.
9. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8, 101-112.
10. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, FaganAM, IwatsuboT, JackCRJr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH (2011) Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 280-292.
11. Terry RD (2006) Alzheimer's disease and the aging brain. J Geriatr Psychiatry Neurol 19, 125-128.
12. Masliah E, Mallory M, Hansen L, DeTeresa R, Terry RD (1993) Quantitative synaptic alterations in the human neocortex during normal aging. Neurology 43, 192-197.
13. Liu X, Erikson C, Brun A (1996) Cortical synaptic changes and gliosis in normal aging, Alzheimer's disease and frontal lobe degeneration. Dementia 7, 128-134.
14. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R (1991) Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment. Ann Neurol 30, 572-580.
15. DeKosky ST, Scheff SW (1990) Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity. Ann Neurol 27, 457-464.
16. Scheff SW, Price DA, Schmitt FA, Mufson EJ (2006) Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment. Neurobiol Aging 27, 1372-1384.
17. Scheff SW, Price DA, Schmitt FA, Scheff MA, Mufson EJ (2011) Synaptic loss in the inferior temporal gyrus in mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis 24, 547-557.
18. Scheff SW, Price DA, Schmitt FA, DeKosky ST, Mufson EJ (2007) Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology 68, 1501-1508.
19. Mosconi L, Pupi A, De Leon MJ (2008) Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease. Ann N Y Acad Sci 1147, 180-195.
20. HerholzK(2012) Use ofFDGPET as an imaging biomarker in clinical trials of Alzheimer's disease. Biomark Med 6, 431-439.
21. Brickman AM, Small SA, Fleisher A (2009) Pinpointing synaptic loss caused by Alzheimer's disease with fMRI. Behav Neurol 21, 93-100.
22. Siegel M, Donner TH, Engel AK (2012) Spectral fingerprints of large-scale neuronal interactions. Nat Rev Neurosci 13, 121-134.
23. Stam CJ (2011) Dementia and EEG. In Niedermeyer's Electroencephalography: Basic Principles, Clinical Applications and Related Fields, Schomer DL, Lopes da Silva FH, eds. Lippincott Williams & Wilkins/Wolters Kluwer, Philadelphia, PA, pp. 375-394.
24. Cook IA, Leuchter AF (1996) Synaptic dysfunction in Alzheimer's disease: Clinical assessment using quantitative EEG. Behav Brain Res 78, 15-23.
25. deWilde MC, Kamphuis PJ, Sijben JW, Scheltens P (2011) Utility of imaging for nutritional intervention studies in Alzheimer's disease. Eur J Pharmacol 668(Suppl 1), S59-S69.
26. Sperling RA, Karlawish J, Johnson KA (2013) Preclinical Alzheimer disease-The challenges ahead. Nat Rev Neurol 9, 54-58.
27. vanMeer G, Voelker DR, FeigensonGW(2008) Membrane lipids: Where they are and how they behave. Nat Rev Mol Cell Biol 9, 112-124.
28. Mielke MM, Lyketsos CG (2006) Lipids and the pathogenesis of Alzheimer's disease: Is there a link? Int Rev Psychiatry 18, 173-186.
29. Nitsch RM, Blusztajn JK, Pittas AG, Slack BE, Growdon JH, Wurtman RJ (1992) Evidence for a membrane defect in Alzheimer disease brain. Proc Natl Acad Sci U S A 89, 1671-1675.
30. Gottfries CG, Karlsson I, Svennerholm L (1996) Membrane components separate early-onset Alzheimer's disease from senile dementia of the Alzheimer type. Int Psychogeriatr 8, 365-372.
31. Prasad MR, Lovell MA, Yatin M, Dhillon H, Markesbery WR (1998) Regional membrane phospholipid alterations in Alzheimer's disease. Neurochem Res 23, 81-88.
32. Pettegrew JW, Panchalingam K, Hamilton RL, McClure RJ (2001) Brain membrane phospholipid alterations in Alzheimer's disease. Neurochem Res 26, 771-782.
33. Grimm MO, Grosgen S, Riemenschneider M, Tanila H, Grimm HS, Hartmann T (2011) From brain to food: Analysis of phosphatidylcholins, lyso- phosphatidylcholins and phosphatidylcholin-plasmalogens derivates in Alzheimer's disease human post mortem brains and mice model via mass spectrometry. J Chromatogr A 1218, 7713-7722.
34. Igarashi M, Ma K, Gao F, Kim HW, Rapoport SI, Rao JS (2011) Disturbed choline plasmalogen and phospholipid fatty acid concentrations in Alzheimer's disease prefrontal cortex. J Alzheimers Dis 24, 507-517.
35. Grimm MO, Kuchenbecker J, Rothhaar TL, Grosgen S, Hundsdorfer B, Burg VK, Friess P, Muller U, Grimm HS, Riemenschneider M, Hartmann T (2011) Plasmalogen synthesis is regulated via alkyl-dihydroxyacetonephosphatesynthase by amyloid precursor protein processing and is affected in Alzheimer's disease. J Neurochem 116, 916-925.
36. Soderberg M, Edlund C, Kristensson K, Dallner G (1991) Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease. Lipids 26, 421-425.
37. Astarita G, Jung KM, Berchtold NC, Nguyen VQ, Gillen DL, Head E, Cotman CW, Piomelli D (2010) Deficient liver biosynthesis of docosahexaenoic acid correlates with cognitive impairment in Alzheimer's disease. PLoS One 5, e12538.
38. Nakada T, Kwee IL, Ellis WG (1990) Membrane fatty acid composition shows delta-6-desaturase abnormalities in Alzheimer's disease. Neuroreport 1, 153-155.
39. Cunnane SC, Schneider JA, Tangney C, Tremblay-Mercier J, Fortier M, Bennett DA, Morris MC (2012) Plasma and brain fatty acid profiles in mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis 29, 691-697.
40. Martin V, Fabelo N, Santpere G, Puig B, Marin R, Ferrer I, Diaz M (2010) Lipid alterations in lipid rafts from Alzheimer's disease human brain cortex. J Alzheimers Dis 19, 489-502.
41. Han X (2010) Multi-dimensional mass spectrometry-based shotgun lipidomics and the altered lipids at the mild cog nitive impairment stage of Alzheimer's disease. Biochim Biophys Acta 1801, 774-783.
42. Yehuda S, Rabinovitz S, Carasso RL, Mostofsky DI (2002) The role of polyunsaturated fatty acids in restoring the aging neuronal membrane. Neurobiol Aging 23, 843-853.
43. Haag M (2003) Essential fatty acids and the brain. Can J Psychiatry 48, 195-203.
44. Vigh L, Escriba PV, Sonnleitner A, Sonnleitner M, Piotto S, Maresca B, Horvath I, Harwood JL (2005) The significance of lipid composition for membrane activity: New concepts and ways of assessing function. Prog Lipid Res 44, 303-344.
45. Bourre JM (2006) Effects of nutrients (in food) on the structure and function of the nervous system: Update on dietary requirements for brain. Part 2: Macronutrients. J Nutr Health Aging 10, 386-399.
46. Bourre JM (2006) Effects of nutrients (in food) on the structure and function of the nervous system: Update on dietary requirements for brain. Part 1: Micronutrients. J Nutr Health Aging 10, 377-385.
47. Sastry PS (1985) Lipids of nervous tissue: Composition and metabolism. Prog Lipid Res 24, 69-176.
48. KennedyEP,WeissSB(1956) The function of cytidine coenzymes in the biosynthesis of phospholipides. J Biol Chem 222, 193-214.
49. Vance JE, Vance DE (2004) Phospholipid biosynthesis in mammalian cells. Biochem Cell Biol 82, 113-128.
50. Wurtman RJ, Cansev M, Sakamoto T, Ulus IH (2009) Use of phosphatide precursors to promote synaptogenesis. Annu Rev Nutr 29, 59-87.
51. Liu SY, Tardi PG, Choy PC, Man RY (1993) Effects of selenium supplement on the de novo biosynthesis of glycerolipids in the isolated rat heart. Biochim Biophys Acta 1170, 307-313.
52. Richardson UI, Watkins CJ, Pierre C, Ulus IH, Wurtman RJ (2003) Stimulation of CDP-choline synthesis by uridine or cytidine in PC12 rat pheochromocytoma cells. Brain Res 971, 161-167.
53. Pooler AM, Guez DH, Benedictus R, Wurtman RJ (2005) Uridine enhances neurite outgrowth in nerve growth factordifferentiated PC12. Neuroscience 134, 207-214.
54. Wurtman RJ, Regan M, Ulus I, Yu L (2000) Effect of oral CDP-choline on plasma choline and uridine levels in humans. Biochem Pharmacol 60, 989-992.
55. Ulus IH, Watkins CJ, Cansev M, Wurtman RJ (2006) Cytidine and uridine increase striatal CDP-choline levels without decreasing acetylcholine synthesis or release. Cell Mol Neurobiol 26, 563-577.
56. Millington WR,Wurtman RJ (1982) Choline administration elevates brain phosphorylcholine concentrations. J Neurochem 38, 1748-1752.
57. Cansev M, Watkins CJ, van der Beek EM, Wurtman RJ (2005) Oral uridine-5-monophosphate (UMP) increases brain CDP-choline levels in gerbils. Brain Res 1058, 101-108.
58. Agarwal N, Sung YH, Jensen JE, daCunha G, Harper D, Olson D, Renshaw PF (2010) Short-Term administration of uridine increases brain membrane phospholipid precursors in healthy adults: A 31-phosphorus magnetic resonance spectroscopy study at 4T. Bipolar Disord 12, 825-833.
59. Richardson UI, Wurtman RJ (2007) Polyunsaturated fatty acids stimulate phosphatidylcholine synthesis in PC12 cells. Biochim Biophys Acta 1771, 558-563.
60. Cansev M, Wurtman RJ (2007) Chronic administration of docosahexaenoic acid or eicosapentaenoic acid, but not arachidonic acid, alone or in combination with uridine, increases brain phosphatide and synaptic protein levels in gerbils. Neuroscience 148, 421-431.
61. Cansev M, Marzloff G, Sakamoto T, Ulus IH, Wurtman RJ (2009) Giving uridine and/or docosahexaenoic acid orally to rat dams during gestation and nursing increases synaptic elements in brains of weanling pups. Dev Neurosci 31, 181-192.
62. CansevM, Ulus IH,Wang L, Maher TJ,Wurtman RJ (2008) Restorative effects of uridine plus docosahexaenoic acid in a rat model of Parkinson's disease. Neurosci Res 62, 206-209.
63. Holguin S, Huang Y, Liu J, Wurtman R (2008) Chronic administration of DHA and UMP improves the impaired memory of environmentally impoverished rats. Behav Brain Res 191, 11-16.
64. Holguin S, Martinez J, Chow C,Wurtman R (2008) Dietary uridine enhances the improvement in learning and memory produced by administering DHA to gerbils. FASEB J 22, 3938-3946.
65. Sakamoto T, Cansev M, Wurtman RJ (2007) Oral supplementation with docosahexaenoic acid and uridine-5'-monophosphate increases dendritic spine density in adult gerbil hippocampus. Brain Res 1182, 50-59.
66. Wurtman RJ, Ulus IH, Cansev M, Watkins CJ, Wang L, Marzloff G (2006) Synaptic proteins and phospholipids are increased in gerbil brain by administering uridine plus docosahexaenoic acid orally. Brain Res 1088, 83-92.
67. Moore SA, Yoder E, Murphy S, Dutton GR, Spector AA (1991) Astrocytes, not neurons, produce docosahexaenoic acid (22:6 omega-3) and arachidonic acid (20:4 omega-6). J Neurochem 56, 518-524.
68. Hashimoto M, Hossain S, Tanabe Y, Kawashima A, Harada T, Yano T, Mizuguchi K, Shido O (2009) The protective effect of dietary eicosapentaenoic acid against impairment of spatial cognition learning ability in rats infused with amyloid beta(1-40). J Nutr Biochem 20, 965-973.
69. Wang CS, Lee RK (2000) Choline plus cytidine stimulate phospholipid production, and the expression and secretion of amyloid precursor protein in rat PC12 cells. Neurosci Lett 283, 25-28.
70. Akbar M, Calderon F, Wen Z, Kim HY (2005) Docosahexaenoic acid: A positive modulator of Akt signaling in neuronal survival. Proc Natl Acad Sci U S A 102, 10858-10863.
71. Shahdat H, Hashimoto M, Shimada T, Shido O (2004) Synaptic plasma membrane-bound acetylcholinesterase activity is not affected by docosahexaenoic acid-induced decrease in membrane order. Life Sci 74, 3009-3024.
72. de Wilde MC, Penke B, van der Beek EM, Kuipers AA, Kamphuis PJ, Broersen LM (2011) Neuroprotective effects of a specific multi-nutrient intervention against Abeta42-induced toxicity in rats. J Alzheimers Dis 27, 327-339.
73. Arterburn LM, Hall EB, Oken H (2006) Distribution, interconversion, and dose response of n-3 fatty acids in humans. Am J Clin Nutr 83, 1467S-1476S.
74. Wurtman RJ, Hirsch MJ, Growdon JH (1977) Lecithin consumption raises serum-free-choline levels. Lancet 2, 68-69.
75. Smith AD, Smith SM, de Jager CA, Whitbread P, Johnston C, Agacinski G, Oulhaj A, BradleyKM,Jacoby R, RefsumH (2010) Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: A randomized controlled trial. PLoS One 5, e12244.
76. Cansev M (2006) Uridine and cytidine in the brain: Their transport and utilization. Brain Res Rev 52, 389-397.
77. Rapoport SI, Chang MC, Spector AA (2001) Delivery and turnover of plasma-derived essential PUFAs in mammalian brain. J Lipid Res 42, 678-685.
78. Connor WE, Neuringer M, Lin DS (1990) Dietary effects on brain fatty acid composition: The reversibility of n-3 fatty acid deficiency and turnover of docosahexaenoic acid in the brain, erythrocytes, and plasma of rhesus monkeys. J Lipid Res 31, 237-247.
79. Brossard N, Croset M, Lecerf J, Pachiaudi C, Normand S, Chirouze V, Macovschi O, Riou JP, Tayot JL, Lagarde M (1996) Metabolic fate of an oral tracer dose of [13C]docosahexaenoic acid triglycerides in the rat. Am J Physiol 270, R846-R854.
80. Cohen EL,Wurtman RJ (1976) Brain acetylcholine: Control by dietary choline. Science 191, 561-562.
81. Klein J, Koppen A, Loffelholz K (1990) Small rises in plasma choline reverse the negative arteriovenous difference of brain choline. J Neurochem 55, 1231-1236.
82. Yan J, Wang W, Gregory JF 3rd, Malysheva O, Brenna JT, Stabler SP, Allen RH, Caudill MA (2011) MTHFR C677T genotype influences the isotopic enrichment of onecarbon metabolites in folate-compromised men consuming d9-choline. Am J Clin Nutr 93, 348-355.
83. Park EI, Garrow TA (1999) Interaction between dietary methionine and methyl donor intake on rat liver betainehomocysteine methyltransferase gene expression and organization of the human gene. J Biol Chem 274, 7816-7824.
84. Jacob RA, Jenden DJ, Allman-Farinelli MA, SwendseidME (1999) Folate nutriture alters choline status of women and men fed low choline diets. J Nutr 129, 712-717.
85. Holm PI, Bleie O, Ueland PM, Lien EA, Refsum H, Nordrehaug JE, Nygard O (2004) Betaine as a determinant of postmethionine load total plasma homocysteine before and after B-vitamin supplementation. Arterioscler Thromb Vasc Biol 24, 301-307.
86. Watkins SM, Zhu X, Zeisel SH (2003) Phosphatidylethanolamine-N- methyltransferase activity and dietary choline regulate liver-plasma lipid flux and essential fatty acid metabolism in mice. J Nutr 133, 3386-3391.
87. Selley ML (2007) A metabolic link between Sadenosylhomocysteine and polyunsaturated fatty acid metabolism in Alzheimer's disease. Neurobiol Aging 28, 1834-1839.
88. Pynn CJ, Henderson NG, Clark H, Koster G, Bernhard W, Postle AD (2011) Specificity and rate of human and mouse liver and plasma phosphatidylcholine synthesis analyzed in vivo. J Lipid Res 52, 399-407.
89. vanWijk N,Watkins CJ, BohlkeM,Maher TJ, Hageman RJ, Kamphuis PJ, Broersen LM, Wurtman RJ (2012) Plasma choline concentration varies with different dietary levels of vitamins B6, B12 and folic acid in rats maintained on choline-Adequate diets. Br J Nutr 107, 1408-1412.
90. van Wijk N, Watkins CJ, Hageman RJ, Sijben JW, Kamphuis PJ, Wurtman RJ, Broersen LM (2012) Combined dietary folate, vitamin B-12, and vitamin B-6 intake influences plasma docosahexaenoic acid concentration in rats. Nutr Metab 9, 49.
91. Van Dam F, Van Gool WA (2009) Hyperhomocysteinemia and Alzheimer's disease: A systematic review. Arch Gerontol Geriatr 48, 425-430.
92. Magil SG, Zeisel SH,Wurtman RJ (1981) Effects of ingesting soy or egg lecithins on serum choline, brain choline and brain acetylcholine. J Nutr 111, 166-170.
93. van Wijk N, Hageman RJ, Kamphuis PJ, Broersen LM, Sijben JW (2011) Specific nutrients to increase availability of components involved in neuronal membrane synthesis. Alzheimers Dement 7, S665-S666.
94. Jones DB, Hancock JD, Harmon DL, Walker CE (1992) Effects of exogenous emulsifiers and fat sources on nutrient digestibility, serum lipids, and growth performance in weanling pigs. J Anim Sci 70, 3473-3482.
95. O'Doherty PJ, Kakis G, Kuksis A (1973) Role of luminal lecithin in intestinal fat absorption. Lipids 8, 249-255.
96. Nishimukai M, Hara H (2007) Soybean phosphatidylcholine-induced enhancement of lymphatic absorption of triglyceride depends on chylomicron formation in rats. Biosci Biotechnol Biochem 71, 1192-1197.
97. Cybulski LE, de Mendoza D (2011) Bilayer hydrophobic thickness and integral membrane protein function. Curr Protein Pept Sci 12, 760-766.
98. Andersen OS, Koeppe RE 2nd (2007) Bilayer thickness and membrane protein function: An energetic perspective. Annu Rev Biophys Biomol Struct 36, 107-130.
99. Eyster KM (2007) The membrane and lipids as integral participants in signal transduction: Lipid signal transduction for the non-lipid biochemist. Adv Physiol Educ 31, 5-16.
100. Farooqui AA (2012) Lipid mediators and their metabolism in the nucleous: Implications for Alzheimer's disease. J Alzheimers Dis 30(Suppl 2), S163-S178.
101. de Wilde MC, van der Beek EM, Kiliaan AJ, Leenders I, Kuipers AA, Kamphuis PJ, Broersen LM (2010) Docosahexaenoic acid reduces amyloid-beta secretion in human AbetaPP-Transfected CHO-cells by mechanisms other than inflammation related to PGE. J Alzheimers Dis 21, 1271-1281.
102. Hashimoto M, Hossain S, Shimada T, Shido O (2006) Docosahexaenoic acid-induced protective effect against impaired learning in amyloid beta-infused rats is associated with increased synaptosomal membrane fluidity. Clin Exp Pharmacol Physiol 33, 934-939.
103. Favreliere S, Perault MC, Huguet F, De Javel D, Bertrand N, Piriou A, Durand G (2003) DHA-enriched phospholipid diets modulate age-related alterations in rat hippocampus. Neurobiol Aging 24, 233-243.
104. de Wilde MC, Hogyes E, Kiliaan AJ, Farkas T, Luiten PG, Farkas E (2003) Dietary fatty acids alter blood pressure, behavior and brain membrane composition of hypertensive rats. Brain Res 988, 9-19.
105. Broersen LM, Kuipers AA, Balvers M, vanWijk N, Savelkoul PJ, deWildeMC,van der BeekEM,SijbenJW, Hageman RJ, Kamphuis PJ, Kiliaan AJ (2013) A specific multinutrient diet reduces Alzheimer-like pathology in young adult AbetaPPswe/PS1dE9 mice. J Alzheimers Dis 33, 177-190.
106. Axelsen PH,Komatsu H, Murray IV (2011) Oxidative stress and cell membranes in the pathogenesis of Alzheimer's disease. Physiology 26, 54-69.
107. Gutteridge JM (1995) Lipid peroxidation and antioxidants as biomarkers of tissue damage. Clin Chem 41, 1819-1828.
108. Switzer BR, Summer GK (1972) Collagen synthesis in human skin fibroblasts: Effects of ascorbate, -ketoglutarate and ferrous ion on proline hydroxylation. J Nutr 102, 721-728.
109. Fox MA, Sanes JR, Borza DB, Eswarakumar VP, Fassler R, Hudson BG, John SW, Ninomiya Y, Pedchenko V, Pfaff SL, Rheault MN, Sado Y, Segal Y, Werle MJ, Umemori H (2007) Distinct target-derived signals organize formation, maturation, and maintenance of motor nerve terminals. Cell 129, 179-193.
110. Peters MM, Hill KE, Burk RF, Weeber EJ (2006) Altered hippocampus synaptic function in selenoprotein P deficient mice. Mol Neurodegener 1, 12.
111. Lucy JA (1972) Functional and structural aspects of biological membranes: A suggested structural role for vitamin E in the control of membrane permeability and stability. Ann N Y Acad Sci 203, 4-11.
112. Quinn PJ (2004) Is the distribution of alpha-Tocopherol in membranes consistent with its putative functions? Biochemistry 69, 58-66.
113. Monroe EB, Jurchen JC, Lee J, Rubakhin SS, Sweedler JV (2005) Vitamin E imaging and localization in the neuronal membrane. J Am Chem Soc 127, 12152-12153.
114. Trachtenberg JT, Chen BE, Knott GW, Feng G, Sanes JR, Welker E, Svoboda K (2002) Long-Term in vivo imaging of experience-dependent synaptic plasticity in adult cortex. Nature 420, 788-794.
115. Lardi-Studler B, Fritschy JM (2007) Matching of pre- And postsynaptic specializations during synaptogenesis. Neuroscientist 13, 115-126.
116. Wurtman RJ, Cansev M, Sakamoto T, Ulus I (2010) Nutritional modifiers of aging brain function: Use of uridine and other phosphatide precursors to increase formation of brain synapses. Nutr Rev 68(Suppl 2), S88-101.
117. Cansev M, Wurtman RJ, Sakamoto T, Ulus IH (2008) Oral administration of circulating precursors for membrane phosphatides can promote the synthesis of new brain synapses. Alzheimers Dement 4, S153-S168.
118. Calderon F, Kim HY (2004) Docosahexaenoic acid promotes neurite growth in hippocampal neurons. J Neurochem 90, 979-988.
119. Cao D,Kevala K,KimJ,MoonHS, Jun SB, Lovinger D,Kim HY (2009) Docosahexaenoic acid promotes hippocampal neuronal development and synaptic function. J Neurochem 111, 510-521.
120. He C, Qu X, Cui L,Wang J, Kang JX (2009) Improved spatial learning performance of fat-1 mice is associated with enhanced neurogenesis and neuritogenesis by docosahexaenoic acid. Proc Natl Acad Sci U S A 106, 11370-11375.
121. Shrivastava R, Vincent B, Gobron S, Cucuat N, John GW (2005) Evidence for growth-promoting effects of omega n-3 fatty acids alone and in combination with a specific vitamin and mineral complex in rat neuroblastoma cells. Nutr Neurosci 8, 317-321.
122. Fujii A, Matsumoto H, Yamamoto H (1996) Effect of vitaminBcomplex on neurotransmission and neurite outgrowth. Gen Pharmacol 27, 995-1000.
123. Wang L, Pooler AM, Albrecht MA, Wurtman RJ (2005) Dietary uridine-5-monophosphate supplementation increases potassium-evoked dopamine release and promotes neurite outgrowth in aged rats. J Mol Neurosci 27, 137-145.
124. Calon F, Lim GP, Yang F, Morihara T, Teter B, Ubeda O, Rostaing P, Triller A, Salem N Jr, Ashe KH, Frautschy SA, Cole GM (2004) Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron 43, 633-645.
125. Toni N, Teng EM, Bushong EA, Aimone JB, Zhao C, Consiglio A, van Praag H, Martone ME, Ellisman MH, Gage FH (2007) Synapse formation on neurons born in the adult hippocampus. Nat Neurosci 10, 727-734.
126. Knott GW, Holtmaat A, Wilbrecht L, Welker E, Svoboda K (2006) Spine growth precedes synapse formation in the adult neocortex in vivo. Nat Neurosci 9, 1117-1124.
127. Aid S, Vancassel S, Linard A, Lavialle M, Guesnet P (2005) Dietary docosahexaenoic acid [22:6(n-3)] as a phospholipid or a triglyceride enhances the potassium chloride-evoked release of acetylcholine in rat hippocampus. J Nutr 135, 1008-1013.
128. Aid S, Vancassel S, Poumes-Ballihaut C, Chalon S, Guesnet P, Lavialle M (2003) Effect of a diet-induced n-3 PUFA depletion on cholinergic parameters in the rat hippocampus. J Lipid Res 44, 1545-1551.
129. Wang L, Albrecht MA, Wurtman RJ (2007) Dietary supplementation with uridine-5'-monophosphate (UMP), a membrane phosphatide precursor, increases acetylcholine level and release in striatum of aged rat. Brain Res 1133, 42-48.
130. Ulus IH, Wurtman RJ, Mauron C, Blusztajn JK (1989) Choline increases acetylcholine release and protects against the stimulation-induced decrease in phosphatide levels within membranes of rat corpus striatum. Brain Res 484, 217-227.
131. Beninger RJ, Tighe SA, Jhamandas K (1984) Effects of chronic manipulations of dietary choline on locomotor activity, discrimination learning and cortical acetylcholine release in aging adult Fisher 344 rats. Neurobiol Aging 5, 29-34.
132. Savelkoul PJ, Janickova H, Kuipers AA, Hageman RJ, Kamphuis PJ, Dolezal V, Broersen LM (2012) A specific multi-nutrient formulation enhances M1 muscarinic acetylcholine receptor responses in vitro. J Neurochem 120, 631-640.
133. Kihara T, Shimohama S (2004) Alzheimer's disease and acetylcholine receptors. Acta Neurobiol Exp 64, 99-105.
134. Calon F, Lim GP, Morihara T, Yang F, Ubeda O, Salem N Jr, Frautschy SA, Cole GM (2005) Dietary n-3 polyunsaturated fatty acid depletion activates caspases and decreases NMDA receptors in the brain of a transgenic mouse model of Alzheimer's disease. Eur J Neurosci 22, 617-626.
135. Farkas E, de Wilde MC, Kiliaan AJ, Meijer J, Keijser JN, Luiten PG (2002) Dietary long chain PUFAs differentially affect hippocampal muscarinic 1 and serotonergic 1A receptors in experimental cerebral hypoperfusion. Brain Res 954, 32.
136. Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL (2007) Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-Type glutamate receptordependent signaling pathway. J Neurosci 27, 2866-2875.
137. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM,Walsh DM, Sabatini BL, Selkoe DJ (2008) Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14, 837-842.
138. Bittner T, Burgold S, Dorostkar MM, Fuhrmann M, Wegenast-Braun BM, Schmidt B, Kretzschmar H, Herms J (2012) Amyloid plaque formation precedes dendritic spine loss. Acta Neuropathol 124, 797-807.
139. Williamson R, Sutherland C (2011) Neuronal membranes are key to the pathogenesis of Alzheimer's disease: The role of both raft and non-raft membrane domains. Curr Alzheimer Res 8, 213-221.
140. Eckert GP,Wood WG,Muller WE (2010) Lipid membranes and beta-Amyloid: A harmful connection. Curr Protein Pept Sci 11, 319-325.
141. Florent-Bechard S, Desbene C, Garcia P, Allouche A, Youssef I, Escanye MC, Koziel V, Hanse M, Malaplate-Armand C, Stenger C, Kriem B, Yen-Potin FT, Olivier JL, Pillot T, Oster T (2009) The essential role of lipids in Alzheimer's disease. Biochimie 91, 804-809.
142. Hartmann T, Kuchenbecker J, Grimm MO (2007) Alzheimer's disease: The lipid connection. J Neurochem 103(Suppl 1), 159-170.
143. Grimm MO, Kuchenbecker J, Grosgen S, Burg VK, Hundsdorfer B, Rothhaar TL, Friess P, de Wilde MC, Broersen LM, Penke B, Peter M, Vigh L, Grimm HS, Hartmann T (2011) Docosahexaenoic acid reduces amyloid beta production via multiple pleiotropic mechanisms. J Biol Chem 286, 14028-14039.
144. Wolozin B (2001) A fluid connection: Cholesterol and Abeta. Proc Natl Acad Sci U S A 98, 5371-5373.
145. Winkler E, Kamp F, Scheuring J, Ebke A, Fukumori A, Steiner H (2012) Generation of Alzheimer diseaseassociated amyloid beta42/43 peptide by gamma-secretase can be inhibited directly by modulation of membrane thickness. J Biol Chem 287, 21326-21334.
146. Sahlin C, Pettersson FE, Nilsson LN, Lannfelt L, JohanssonAS(2007) Docosahexaenoic acid stimulates nonamyloidogenic APP processing resulting in reduced Abeta levels in cellular models of Alzheimer's disease. Eur J Neurosci 26, 882-889.
147. Oksman M, Iivonen H, Hogyes E, Amtul Z, Penke B, Leenders I, Broersen L, Lutjohann D, Hartmann T, Tanila H (2006) Impact of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on beta-Amyloid accumulation in APP/PS1 transgenic mice. Neurobiol Dis 23, 563-572.
148. Florent S, Malaplate-Armand C, Youssef I, Kriem B, Koziel V, Escanye MC, Fifre A, Sponne I, Leininger-Muller B, Olivier JL, Pillot T, Oster T (2006) Docosahexaenoic acid prevents neuronal apoptosis induced by soluble amyloidbeta oligomers. J Neurochem 96, 385-395.
149. Amtul Z, Uhrig M, Supino R, Beyreuther K (2010) Phospholipids and a phospholipid-rich diet alter the in vitro amyloid-beta peptide levels and amyloid-beta 42/40 ratios. Neurosci Lett 481, 73-77.
150. Fuso A, Nicolia V, Cavallaro RA, Ricceri L, D'Anselmi F, Coluccia P, Calamandrei G, Scarpa S (2008) B-vitamin deprivation induces hyperhomocysteinemia and brain S-Adenosylhomocysteine, depletes brain Sadenosylmethionine, and enhances PS1 and BACE expression and amyloid-beta deposition in mice. Mol Cell Neurosci 37, 731-746.
151. Zhuo JM, Pratico D (2010) Acceleration of brain amyloidosis in an Alzheimer's disease mouse model by a folate, vitamin B6 and B12-deficient diet. Exp Gerontol 45, 195-201.
152. Conte V, Uryu K, Fujimoto S, Yao Y, Rokach J, Longhi L, Trojanowski JQ, Lee VM, McIntosh TK, Pratico D (2004) Vitamin E reduces amyloidosis and improves cognitive function in Tg2576 mice following repetitive concussive brain injury. J Neurochem 90, 758-764.
153. Sung S, Yao Y, Uryu K, Yang H, Lee VM, Trojanowski JQ, Pratico D (2004) Early vitamin E supplementation in young but not aged mice reduces Abeta levels and amyloid deposition in a transgenic model of Alzheimer's disease. FASEB J 18, 323-325.
154. Lim GP, Calon F, Morihara T, Yang F, Teter B, Ubeda O, Salem N Jr, Frautschy SA, Cole GM (2005) A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J Neurosci 25, 3032-3040.
155. Green KN, Martinez-Coria H, Khashwji H, Hall EB, Yurko-Mauro KA, Ellis L, LaFerla FM (2007) Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid-beta and tau pathology via a mechanism involving presenilin 1 levels. J Neurosci 27, 4385-4395.
156. Hooijmans CR, Van der Zee CE, Dederen PJ, Brouwer KM, Reijmer YD, van Groen T, Broersen LM, Lutjohann D, Heerschap A, Kiliaan AJ (2009) DHA and cholesterol containing diets influence Alzheimer-like pathology, cognition and cerebral vasculature in APPswe/PS1dE9 mice. Neurobiol Dis 33, 482-498.
157. Hooijmans CR, Rutters F, Dederen PJ, Gambarota G,Veltien A, van Groen T, Broersen LM, Lutjohann D, Heerschap A, Tanila H, Kiliaan AJ (2007) Changes in cerebral blood volume and amyloid pathology in aged Alzheimer APP/PS1 mice on a docosahexaenoic acid (DHA) diet or cholesterol enriched Typical Western Diet (TWD). Neurobiol Dis 28, 16-29.
158. ArendashGW, Jensen MT, Salem N Jr, Hussein N, Cracchiolo J, Dickson A, Leighty R, Potter H (2007) A diet high in omega-3 fatty acids does not improve or protect cognitive performance in Alzheimer's transgenic mice. Neuroscience 149, 286-302.
159. Arsenault D, Julien C, Tremblay C, Calon F (2011) DHA improves cognition and prevents dysfunction of entorhinal cortex neurons in 3xTg-AD mice. PLoS One 6, e17397.
160. Gamoh S, Hashimoto M, Sugioka K, Shahdat HM, Hata N, Misawa Y, Masumura S (1999) Chronic administration of docosahexaenoic acid improves reference memory-related learning ability in young rats. Neuroscience 93, 237-241.
161. Hashimoto M, Hossain S, Shimada T, Sugioka K, Yamasaki H, Fujii Y, Ishibashi Y, Oka J, Shido O (2002) Docosahexaenoic acid provides protection from impairment of learning ability in Alzheimer's disease model rats. J Neurochem 81, 1084-1091.
162. Hashimoto M, Tanabe Y, Fujii Y, Kikuta T, Shibata H, Shido O (2005) Chronic administration of docosahexaenoic acid ameliorates the impairment of spatial cognition learning ability in amyloid beta-infused rats. J Nutr 135, 549-555.
163. Petursdottir AL, Farr SA, Morley JE, BanksWA, Skuladottir GV (2008) Effect of dietary n-3 polyunsaturated fatty acids on brain lipid fatty acid composition, learning ability, and memory of senescence-Accelerated mouse. J GerontolABiol Sci Med Sci 63, 1153-1160.
164. Teather LA, Wurtman RJ (2006) Chronic administration of UMP ameliorates the impairment of hippocampaldependent memory in impoverished rats. J Nutr 136, 2834-2837.
165. Lim SY, Suzuki H (2000) Intakes of dietary docosahexaenoic acid ethyl ester and egg phosphatidylcholine improve maze-learning ability in young and old mice. J Nutr 130, 1629-1632.
166. De Bruin NM, Kiliaan AJ, De Wilde MC, Broersen LM (2003) Combined uridine and choline administration improves cognitive deficits in spontaneously hypertensive rats. Neurobiol Learn Mem 80, 63-79.
167. deWilde M, Farkas E, Gerrits M, Kiliaan A, Luiten P (2002) The effect of n-3 polyunsaturated fatty acid-rich diets on cognitive and cerebrovascular parameters in chronic cerebral hypoperfusion. Brain Res 947, 166.
168. Wiesmann M, Jansen D, Zerbi V, Broersen LM, Garthe A, Kiliaan AJ (2013) Improved spatial learning strategy and memory in aged Alzheimer AbetaPPswe/PS1dE9 mice on a multi-nutrient diet. J Alzheimers Dis 37, 233-245.
169. Broersen LM, Koivisto H, Takalo M, Miettinen P, Tanila H (2011) Special lipid-based diets alleviate cognitive deficits in the APPswe/PS1dE9 transgenic mouse model of Alzheimer's disease independent of brain amyloid deposition. Alzheimers Dement 7, S650.
170. Mi W, van Wijk N, Cansev M, Sijben JW, Kamphuis PJ (2013) Nutritional approaches in the risk reduction and management of Alzheimer's disease. Nutrition 29, 1080-1989.
171. Lopes da Silva S, Vellas B, Elemans S, Luchsinger J, Kamphuis P, Yaffe K, Sijben J, Groenendijk M, Stijnen T (2013) Plasma nutrient status of patients with Alzheimer's disease: Asystematic reviewand meta-Analysis. Alzheimers Dement, DOI: 10.1016/j.jalz.2013.05.1771.
172. Scheltens P, Kamphuis PJ, Verhey FR, Olde Rikkert MG, Wurtman RJ, Wilkinson D, Twisk JW, Kurz A (2010) Efficacy of a medical food in mild Alzheimer's disease: A randomized, controlled trial. Alzheimers Dement 6, 1-10 e11.
173. Shah R, Kamphuis P, Leurgans S, Swinkels S, Sadowsky C, Bongers A, Rappaport S, Quionn J,Wieggers R, Bennett D, Scheltens P (2011) Souvenaid as an add-on intervention in patients with mild to moderate Alzheimer's Disease using Alzheimers's Disease medication: Results from a randomized, controlled, double-blind study (S-Connect). J Nutr Health Aging 15, S30.
174. Scheltens P, Twisk JW, Blesa R, Scarpini E, von Arnim CA, Bongers A, Harrison J, Swinkels SH, Stam CJ, de Waal H, Wurtman RJ, Wieggers RL, Vellas B, Kamphuis PJ (2012) Efficacy of souvenaid in mild Alzheimer's disease: Results from a randomized, controlled trial. J Alzheimers Dis 31, 225-236.